Pfizer Inc. (ETR:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 123.81B |
| Revenue (ttm) | 53.69B |
| Net Income (ttm) | 8.41B |
| Shares Out | n/a |
| EPS (ttm) | 1.48 |
| PE Ratio | 14.73 |
| Forward PE | 8.45 |
| Dividend | 1.53 (6.94%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 50,011 |
| Average Volume | 65,782 |
| Open | 21.81 |
| Previous Close | 21.96 |
| Day's Range | 21.71 - 22.07 |
| 52-Week Range | 18.57 - 26.54 |
| Beta | 0.43 |
| RSI | 56.09 |
| Earnings Date | Nov 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a Nectin-4 directed ant...
Pfizer Inc. (PFE) Completes Significant Public Offering of Notes
Pfizer Inc. (PFE) Completes Significant Public Offering of Notes
Growth is your best defense in any environment, says Jim Cramer
'Mad Money' host Jim Cramer looks at dependable high-yield stocks to add to your portfolio including Pfizer, Enbridge, and Realty Income.
Jim Cramer circles back on dependable high-yield stocks
'Mad Money' host Jim Cramer looks at dependable high-yield stocks to add to your portfolio including Pfizer, Enbridge, and Realty Income.
As the market fluctuates, Jim Cramer names three lower risk stocks with high dividends
CNBC's Jim Cramer explained why Enbridge, Pfizer and Realty Income can be relatively safe investments right now.
Why Are Shares of Pfizer Up Today?
Shares of Pfizer, Inc. (NASDAQ: PFE) are trading higher after a study found that the company’s new mRNA flu vaccine outperforms traditional shots against predominant strains . What To Know: A study p...
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment
U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortu...
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration...
Merck Keytruda formulations approved in U.S. for bladder cancer
Merck (MRK) stock is in focus as the FDA approves its Keytruda versions with Pfizer (PFE) and Astellas' (ALPMF) Padcev for bladder cancer. Read more here.
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
Pfizer Crosses Below Key Moving Average Level
In trading on Thursday, shares of Pfizer crossed below their 200 day moving average of $24.58, changing hands as low as $24.28 per share. Pfizer shares are currently trading off about 1.6% on the day.
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
Pfizer (PFE) Agrees to $41.5 Million Settlement Over Drug Allegations
Pfizer (PFE) Agrees to $41.5 Million Settlement Over Drug Allegations
Is Pfizer's 6.9%-Yielding Dividend Still Safe?
The company's earnings fell by 21% last quarter.
October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs
This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LY...
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and the...
Pfizer: Is This Pharma Giant Finally A Bargain
Pfizer (PFE) and Tris Pharma Settle ADHD Drug Lawsuit for $41.5M
Pfizer (PFE) and Tris Pharma Settle ADHD Drug Lawsuit for $41.5M
Pfizer resolves Texas lawsuit over adulterated ADHD drug in $41.5M settlement
Pfizer in $41.5 million settlement with Texas over ADHD drug
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve claims over alleged quality control lapses in medicine to treat attention deficit hyperactivity disorder in chi...
Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript
Pfizer (PFE) Plans $5 Billion Bond Issuance to Fund Metsera Acquisition
Pfizer (PFE) Plans $5 Billion Bond Issuance to Fund Metsera Acquisition
Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.
Pfizer (PFE) Plans $5B Bond Offering to Support Metsera Acquisition
Pfizer (PFE) Plans $5B Bond Offering to Support Metsera Acquisition